Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does CASIRIVIMAB\IMDEVIMAB Cause Extra dose administered? 12 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 12 reports of Extra dose administered have been filed in association with CASIRIVIMAB\IMDEVIMAB. This represents 0.3% of all adverse event reports for CASIRIVIMAB\IMDEVIMAB.

12
Reports of Extra dose administered with CASIRIVIMAB\IMDEVIMAB
0.3%
of all CASIRIVIMAB\IMDEVIMAB reports
0
Deaths
1
Hospitalizations

How Dangerous Is Extra dose administered From CASIRIVIMAB\IMDEVIMAB?

Of the 12 reports, 1 (8.3%) required hospitalization.

Is Extra dose administered Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for CASIRIVIMAB\IMDEVIMAB. However, 12 reports have been filed with the FAERS database.

What Other Side Effects Does CASIRIVIMAB\IMDEVIMAB Cause?

Infusion related reaction (875) Dyspnoea (687) Nausea (416) Oxygen saturation decreased (390) Dizziness (357) Pyrexia (306) Chest discomfort (294) Chills (265) Flushing (238) Cough (235)

What Other Drugs Cause Extra dose administered?

TIRZEPATIDE (6,774) DULAGLUTIDE (3,047) LORATADINE (1,556) DUPILUMAB (1,422) FEXOFENADINE (1,413) NAPROXEN (908) POLYETHYLENE GLYCOL 3350 (589) ACETAMINOPHEN (552) DALFAMPRIDINE (519) FLUTICASONE\SALMETEROL (499)

Which CASIRIVIMAB\IMDEVIMAB Alternatives Have Lower Extra dose administered Risk?

CASIRIVIMAB\IMDEVIMAB vs CASPOFUNGIN CASIRIVIMAB\IMDEVIMAB vs CATEQUENTINIB CASIRIVIMAB\IMDEVIMAB vs CC-4047 CASIRIVIMAB\IMDEVIMAB vs CEDAZURIDINE\DECITABINE CASIRIVIMAB\IMDEVIMAB vs CEDIRANIB

Related Pages

CASIRIVIMAB\IMDEVIMAB Full Profile All Extra dose administered Reports All Drugs Causing Extra dose administered CASIRIVIMAB\IMDEVIMAB Demographics